Konjac-Mannan Improves Glycemia and Other Risk Factors for CHD in T2DM

Konjac-Mannan (Glucomannan) Improves Glycemia and Other Associated Risk Factors for Coronary Heart Disease in Type 2 Diabetes

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03741660

Enrollment

Registered

2018-11-15

Start date

1991-01-31

Completion date

1998-06-30

Last updated

2018-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 Diabetes, Coronary Heart Disease

Keywords

konjac, type2 diabetes, fiber, coronary heart disease

Brief summary

To examine whether Konjac-mannan fiber improves metabolic control measured by glycemia, lipidemia, and blood pressure in individuals with type-2 diabetes.

Interventions

DIETARY_SUPPLEMENTkonjac glucomannan

Konjac-mannan fiber-enriched biscuits (0.7 g/412KJ \[100kcal\] of glucommanan)

DIETARY_SUPPLEMENTwheat bran

Wheat bran (hard red wheat bran) fiber enriched biscuits

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* hyperlipidemia controlled by medication * hypertension controlled by medication * type 2 diabetes controlled by medication * minimum 3 years since onset of all three conditions * sedentary lifestyle

Exclusion criteria

* regular smoking * regular alcohol consumption * family history of premature coronary heart disease * hypothyroidism * renal, hepatic or gastrointestinal disease

Design outcomes

Primary

Measure	Time frame
change in total:HDL cholesterol	change from baseline at week 3, relative to control
change in fructosamine	change from baseline at week 3, relative to control
change in systolic blood pressure	change from baseline at week 3, relative to control

Secondary

Measure	Time frame
change in apolipoprotein A-1	change from baseline at week 3, relative to control
change in apolipoprotain B	change from baseline at week 3, relative to control
change in glucose	change from baseline at week 3, relative to control
change in total cholesterol	change from baseline at week 3, relative to control
diastolic blood pressure	change from baseline at week 3, relative to control
change in body weight	change from baseline at week 3, relative to control
change in apoB:ApoA-1	change from baseline at week 3, relative to control
change in insulin	change from baseline at week 3, relative to control
change in LDL cholesterol	change from baseline at week 3, relative to control
change in HDL cholesterol	change from baseline at week 3, relative to control

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026